Abstract: The present disclosure discloses an in-vitro method for detecting presence of metabolically altered cells. Also, an in-vitro method for detecting presence of quiescent cells has been disclosed. The present disclosure discloses an in-vitro method for detecting and predicting presence of cancer. The present disclosure discloses an in-vitro method for monitoring response to anti-cancer therapy. The present disclosure analyses expression of at least one biomarker of pluripotent stem cell for detecting or predicting or monitoring cancer. A related use of the at least one biomarker of pluripotent stem cell marker along with a method of treatment comprising the in-vitro method of detection or prediction has been disclosed herewith.

Abstract: A data forwarding device belonging to both (1) a segment routing (SR) domain and (2) a label distribution protocol (LDP) domain may be used to perform a method comprising: (a) receiving, by the data forwarding device, information uniquely associated with each of one or more nodes in the LDP domain; (b) associating, for each of the one or more nodes in the LDP domain, a unique SR segment identifier (SID) with the information uniquely associated with the node in the LDP domain, to generate one or more SR SID-to-LDP node associations; and (c) transmitting the one or more SR SID-to-LDP node associations for propagation to at least one other node in the SR domain, whereby the at least one other node in the SR domain will become aware of the one or more nodes in the LDP domain. The SR-LDP border router is aware of all the nodes in SR and LDP domain including the SRGB database (base label, node label, and label range).

Abstract: Load balancing in a network section implementing VRRPv3 may be supported in a way that is easier to implement than that described in § 4.2 of RFC 5798.

Abstract: The present disclosure discloses an in-vitro method for detecting presence of metabolically altered cells. Also, an in-vitro method for detecting presence of quiescent cells has been disclosed. The present disclosure discloses an in-vitro method for detecting and predicting presence of cancer. The present disclosure discloses an in-vitro method for monitoring response to anti-cancer therapy. The present disclosure analyses expression of at least one biomarker of pluripotent stem cell for detecting or predicting or monitoring cancer. A related use of the at least one biomarker of pluripotent stem cell marker along with a method of treatment comprising the in-vitro method of detection or prediction has been disclosed herewith.

Abstract: A device may determine an acceptance rate threshold associated with a network server. The acceptance rate threshold may be a handling capacity of the network server for processing connection requests. The device may determine that a rate at which a set of connection requests are being received exceeds the acceptance rate threshold. The device may cause a portion of the set of connection requests to be transmitted to the network server via a network tunnel based on determining that the rate at which the set of connection requests are being received exceeds the acceptance rate threshold. The portion of the set of connection requests may be caused to be transmitted at a rate not exceeding the acceptance rate threshold.

Abstract: A device may include one or more processors. The one or more processors may identify a set of network tunnels or network sessions for which a teardown is to be performed. The set of network tunnels or network sessions may be associated with a set of identifiers. The one or more processors may generate a signaling message associated with causing the teardown to be performed on the set of network tunnels or network sessions. The signaling message may include two or more identifiers of the set of identifiers. The one or more processors may transmit the signaling message to cause the teardown to be performed on two or more network tunnels or network sessions, of the set of network tunnels or network sessions, corresponding to the two or more identifiers.